Literature DB >> 16098032

Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis.

Ellen G Pfendner1, Sara G Sadowski, Jouni Uitto.   

Abstract

Epidermolysis bullosa simplex (EBS) is a mechano-bullous disorder characterized by intraepidermal blistering within the basal keratinocytes as a result of trauma to the skin. As part of the DNA diagnostics program, our laboratory has analyzed a cohort of 57 patients with the initial referral diagnosis of EBS. Among these patients, 18 were found to harbor heterozygous mutations in the keratin 5 or keratin 14 genes, KRT5 and KRT14, respectively, whereas in 14 cases, the disease was associated with mutations in both alleles of the plectin gene. Among the keratin mutations, 12 were distinct and six were novel, and in most cases there was no family history of a blistering disease. Prenatal diagnosis of eight pregnancies with keratin gene mutations, at risk for EBS either because one of the parents was affected (three cases) or history of a previously affected child as a result of a de novo mutation (five cases), predicted two fetuses being affected and six being normal. No recurrence of the de novo mutations in these pregnancies was disclosed. Collectively, the data suggest that a significant number of cases diagnosed as EBS are due to plectin mutations, and many cases result from de novo mutations in KRT5 and KRT14 genes. These findings have implications for genetic counseling and prenatal diagnosis for EBS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098032     DOI: 10.1111/j.0022-202X.2005.23818.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants.

Authors:  R Varki; S Sadowski; E Pfendner; J Uitto
Journal:  J Med Genet       Date:  2006-02-10       Impact factor: 6.318

2.  Quantitative model of R-loop forming structures reveals a novel level of RNA-DNA interactome complexity.

Authors:  Thidathip Wongsurawat; Piroon Jenjaroenpun; Chee Keong Kwoh; Vladimir Kuznetsov
Journal:  Nucleic Acids Res       Date:  2011-11-25       Impact factor: 16.971

3.  Novel sporadic and recurrent mutations in KRT5 and KRT14 genes in Polish epidermolysis bullosa simplex patients: further insights into epidemiology and genotype-phenotype correlation.

Authors:  K Wertheim-Tysarowska; M Ołdak; A Giza; A Kutkowska-Kaźmierczak; J Sota; D Przybylska; K Woźniak; D Śniegórska; K Niepokój; A Sobczyńska-Tomaszewska; A M Rygiel; R Płoski; J Bal; C Kowalewski
Journal:  J Appl Genet       Date:  2015-10-02       Impact factor: 3.240

4.  Known and novel mutations responsible for epidermolysis bullosa simplex cases in a Chinese population.

Authors:  Jia Zhang; Yu Ding; Ming Li; Zhirong Yao; Yin Zhuang
Journal:  Exp Ther Med       Date:  2019-10-25       Impact factor: 2.447

5.  A Familial Form of Epidermolysis Bullosa Simplex Associated with a Pathogenic Variant in KRT5.

Authors:  Francesco Paduano; Emma Colao; Teresa Grillone; Marco Flavio Michele Vismara; Rosario Amato; Steven Nisticò; Chiara Mignogna; Stefano Dastoli; Fernanda Fabiani; Rossella Zucco; Francesco Trapasso; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2021-09-25       Impact factor: 4.096

Review 6.  Epidermolysis Bullosa-A Different Genetic Approach in Correlation with Genetic Heterogeneity.

Authors:  Monica-Cristina Pânzaru; Lavinia Caba; Laura Florea; Elena Emanuela Braha; Eusebiu Vlad Gorduza
Journal:  Diagnostics (Basel)       Date:  2022-05-27

Review 7.  Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability.

Authors:  Mbarka Bchetnia; Luigi Bouchard; Jean Mathieu; Philippe M Campeau; Charles Morin; Diane Brisson; Anne-Marie Laberge; Hélène Vézina; Daniel Gaudet; Catherine Laprise
Journal:  J Med Genet       Date:  2021-04-28       Impact factor: 6.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.